← Back to Clinical Trials
Recruiting NCT05080166

UPLYFT For Lymphoma Survivors

Trial Parameters

Condition Lymphoma
Sponsor Dana-Farber Cancer Institute
Study Type INTERVENTIONAL
Phase N/A
Enrollment 74
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-02-08
Completion 2026-05-31
Interventions
Interview with CliniciansField Test of UPLYFT with Lymphoma SurvivorsPilot of UPLYFT with Lymphoma Survivors

Brief Summary

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Eligibility Criteria

Inclusion Criteria: Lymphoma Survivors Phase 1 and 2: * Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma) * Age ≥ 18 years * Interval of 3 months to 24 months from completion of first-line treatment * In complete remission after first line of treatment * Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS). * Access to computer (for videoconferencing) Lymphoma clinicians and mental health clinicians Phase 1: * Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training. * Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians Exclusion Criteria: Lymphoma Survivors Phase 1: * Age \< 18 years * Concurrent other malignancy * Patients with uncontrolled/untreated psyc

Related Trials